Tersera Drug Patent Portfolio
Tersera owns 5 orange book drugs protected by 24 US patents with Qmiiz Odt having the least patent protection, holding only 1 patent. And Varubi with maximum patent protection, holding 10 patents. Given below is the list of Tersera's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9101615 | Intravenous formulations of neurokinin-1 antagonists | 14 Jul, 2032 | Active |
| US7709493 | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use | 28 Feb, 2031 | Active |
| US8193204 | Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use | 27 Feb, 2031 | Active |
| US8545879 | Fast disintegrating compositions of meloxicam | 31 Aug, 2030 | Active |
| US8361500 | Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom | 09 Oct, 2029 | Active |
| US8470842 | Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor | 18 Jan, 2029 | Active |
| US8653094 | Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use | 19 Dec, 2028 | Active |
| US7049320 | NK1 antagonists | 19 Aug, 2028 | Active |
| US7553840 | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use | 11 Dec, 2027 | Active |
| US7968559 | Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds | 11 Dec, 2027 | Active |
| US7563801 | Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same | 04 Apr, 2027 | Active |
| US7981905 | Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same | 04 Apr, 2027 | Active |
| US8178550 | Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor | 04 Apr, 2027 | Active |
| US8404702 | Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same | 04 Apr, 2027 | Active |
| US8653033 | Method for administering omega-conopeptide | 01 Oct, 2024 | Expired |
| US8765680 | Method for administering omega-conopeptide | 01 Oct, 2024 | Expired |
| US9707270 | Method for administering ω-conopeptide | 01 Oct, 2024 | Expired |
| US7049230 | Method of forming a contact plug in a semiconductor device | 08 Dec, 2023 | Expired |
| US8796299 | NK1 antagonists | 17 Dec, 2022 | Expired |
| US7118552 | Automatically operable safety shield system for syringes | 13 Apr, 2022 | Expired |
| US7220247 | Automatically operable safety shield system for syringes | 09 Apr, 2022 | Expired |
| US7500964 | Automatically operable safety shield system for syringes | 26 Feb, 2021 | Expired |
| US5364842 | Method of producing analgesia | 30 Dec, 2016 | Expired |
| US5795864 | Stable omega conopetide formulations | 27 Jun, 2015 | Expired |
Latest Legal Activities on Tersera's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Tersera.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Nov, 2023 | US8193204 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 Nov, 2023 | US8178550 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Feb, 2023 | US9101615 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Jan, 2023 | US7981905 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Dec, 2022 | US7968559 |
| Mail Pub Notice re 312 amendment | 01 Mar, 2022 | US7709493 |
|
Email Notification
Critical
| 01 Mar, 2022 | US7709493 |
| POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION | 25 Feb, 2022 | US7709493 |
| Post Issue Communication - Certificate of Correction Denied | 25 Feb, 2022 | US7709493 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 07 Feb, 2022 | US8796299 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Dec, 2021 | US8765680 |
|
Patent Term Extension Certificate
Critical
| 06 Dec, 2021 | US7709493 |
|
Patent Term Extension Certificate
Critical
| 19 Nov, 2021 | US7049320 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 27 Oct, 2021 | US8193204 |
|
Email Notification
Critical
| 27 Oct, 2021 | US8193204 |
Tersera Drug Patents' Oppositions Filed in EPO
Tersera drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 08, 2017, by Teva Pharmaceutical Industries Ltd. This opposition was filed on patent number EP07774640A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP07774640A | Mar, 2017 | Teva Pharmaceutical Industries Ltd | Revoked |
Tersera's Family Patents
Tersera Drug List
Given below is the complete list of Tersera's drugs and the patents protecting them.
1. Prialt
Prialt is protected by 5 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8653033 | Method for administering omega-conopeptide |
01 Oct, 2024
(7 months ago)
| Expired |
| US8765680 | Method for administering omega-conopeptide |
01 Oct, 2024
(7 months ago)
| Expired |
| US9707270 | Method for administering ω-conopeptide |
01 Oct, 2024
(7 months ago)
| Expired |
| US5364842 | Method of producing analgesia |
30 Dec, 2016
(8 years ago)
| Expired |
| US5795864 | Stable omega conopetide formulations |
27 Jun, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prialt's drug page
2. Qmiiz Odt
Qmiiz Odt is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8545879 | Fast disintegrating compositions of meloxicam |
31 Aug, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qmiiz Odt's drug page
3. Varubi
Varubi is protected by 10 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9101615 | Intravenous formulations of neurokinin-1 antagonists |
14 Jul, 2032
(7 years from now)
| Active |
| US8361500 | Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom |
09 Oct, 2029
(4 years from now)
| Active |
| US8470842 | Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor |
18 Jan, 2029
(3 years from now)
| Active |
| US7049320 | NK1 antagonists |
19 Aug, 2028
(3 years from now)
| Active |
| US7563801 | Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
04 Apr, 2027
(1 year, 10 months from now)
| Active |
| US7981905 | Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
04 Apr, 2027
(1 year, 10 months from now)
| Active |
| US8178550 | Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor |
04 Apr, 2027
(1 year, 10 months from now)
| Active |
| US8404702 | Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
04 Apr, 2027
(1 year, 10 months from now)
| Active |
| US7049230 | Method of forming a contact plug in a semiconductor device |
08 Dec, 2023
(1 year, 5 months ago)
| Expired |
| US8796299 | NK1 antagonists |
17 Dec, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Varubi's drug page
4. Xermelo
Xermelo is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7709493 | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
28 Feb, 2031
(5 years from now)
| Active |
| US8193204 | Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use |
27 Feb, 2031
(5 years from now)
| Active |
| US8653094 | Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use |
19 Dec, 2028
(3 years from now)
| Active |
| US7553840 | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
11 Dec, 2027
(2 years from now)
| Active |
| US7968559 | Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds |
11 Dec, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xermelo's drug page
5. Zoladex
Zoladex is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7118552 | Automatically operable safety shield system for syringes |
13 Apr, 2022
(3 years ago)
| Expired |
| US7220247 | Automatically operable safety shield system for syringes |
09 Apr, 2022
(3 years ago)
| Expired |
| US7500964 | Automatically operable safety shield system for syringes |
26 Feb, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zoladex's drug page